← All trials
NCT00000585
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 1983
- Primary completion
- —
- Completion date
- Oct 1, 1994
- First posted
- —
- Last posted
- —
- Enrollment
- —
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- National Heart, Lung, and Blood Institute (NHLBI)Lead sponsor
- Hoosier Cancer Research NetworkOfficial
- Duke UniversityOfficial
- University of MiamiOfficial
- Columbia UniversityOfficial
- St. Jude Children's HospitalOfficial
- University of CincinnatiOfficial
- Gamble Institute of Medical ResearchOfficial
- East Carolina UniversityOfficial
- George Washington UniversityOfficial
- Icahn School of Medicine at Mount SinaiOfficial
- State University of New York, BrooklynOfficial
- Washington University in St. LouisOfficial
- University of KansasOfficial
- University of MississippiOfficial
- University of Illinois at ChicagoOfficial
- The University of Texas, DallasOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.